A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum
暂无分享,去创建一个
Giovanni Pellacani | Virginia Espina | Alessandra Luchini | Barney Bishop | Enrico Garaci | L. Liotta | G. Pellacani | V. Espina | A. Luchini | E. Garaci | G. Gambara | Emanuel F. Petricoin III | A. Patanarut | B. Bishop | F. Beretti | A. de Pol | Guido Gambara | Barbara Ferrari | Lance A. Liotta | Caterina Longo | Alexis S. Patanarut | Emanuel F. Petricoin III | Francesca Beretti | Anto De Pol | B. Ferrari | Caterina Longo
[1] Virginia Espina,et al. Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles , 2008, Nano research.
[2] R. Webb,et al. In vivo confocal scanning laser microscopy of human skin: melanin provides strong contrast. , 1995, The Journal of investigative dermatology.
[3] C. Longo,et al. Microscopic in vivo description of cellular architecture of dermoscopic pigment network in nevi and melanomas. , 2005, Archives of dermatology.
[4] W. Schempp,et al. Molecular diagnosis in dermatopathology: What makes sense, and what doesn’t , 2009, Experimental dermatology.
[5] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. DePinho,et al. BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.
[7] C. Reynolds,et al. Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy , 2009, Clinical Cancer Research.
[8] J. Hansson,et al. Cisplatin Induces the Proapoptotic Conformation of Bak in a ΔMEKK1-Dependent Manner , 2001, Molecular and Cellular Biology.
[9] David L. Vaux,et al. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.
[10] M. Ferrari,et al. Clinical proteomics: Written in blood , 2003, Nature.
[11] C. Dive,et al. Mitochondrial membrane permeabilisation by Bax/Bak. , 2003, Biochemical and biophysical research communications.
[12] G. Tchernev,et al. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl‐2‐related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings , 2007, Journal of cutaneous pathology.
[13] H. Antoniades,et al. Expression of platelet‐derived growth factor (PDGF)‐A, PDGF‐B and the PDGF‐alpha receptor, but not the PDGF‐beta receptor, in human malignant melanoma in vivo , 1996, The British journal of dermatology.
[14] C. Longo,et al. The impact of in vivo reflectance confocal microscopy for the diagnostic accuracy of melanoma and equivocal melanocytic lesions. , 2007, The Journal of investigative dermatology.
[15] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Eberle,et al. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants , 2003, Oncogene.
[17] S. Seidenari,et al. Reflectance-mode confocal microscopy for the in vivo characterization of pagetoid melanocytosis in melanomas and nevi. , 2005, The Journal of investigative dermatology.
[18] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[19] E. Petricoin,et al. Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. , 2009, Journal of materials chemistry.
[20] S. Joos,et al. The role of Bcl-2 family members in tumorigenesis. , 2004, Biochimica et biophysica acta.
[21] Weidong Zhou,et al. Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers , 2009, PloS one.
[22] S. Cory,et al. The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.
[23] J. Eberle,et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. , 2006, The Journal of investigative dermatology.
[24] Giovanni Pellacani,et al. In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions. , 2009, The Journal of investigative dermatology.
[25] V. Sondak,et al. Markers and tissue resources for melanoma: meeting report. , 2006, Cancer research.
[26] A. Strasser,et al. The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.
[27] Emanuel F. Petricoin,et al. Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer , 2008, Molecular & Cellular Proteomics.
[28] E. Petricoin,et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.
[29] J. Utikal,et al. Tumor biomarkers in melanoma. , 2009, Cancer control : journal of the Moffitt Cancer Center.
[30] Jane Fridlyand,et al. Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.
[31] A Breslow,et al. Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.
[32] C. Belka,et al. Guardians of cell death: the Bcl-2 family proteins. , 2003, Essays in biochemistry.
[33] M. Vinceti,et al. Melanoma epidemic across the millennium: time trends of cutaneous melanoma in Emilia‐Romagna (Italy) from 1997 to 2004 , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.
[34] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[35] Virginia Espina,et al. Protein microarrays: Molecular profiling technologies for clinical specimens , 2003, Proteomics.